Moody's Investors Service ("Moody's") commented that the US emergency use authorization for Pfizer and BioNTech's COVID-19 vaccine is positive for Pfizer's credit profile. The authorization follows recent authorizations in several other countries, including the United Kingdom and Canada, and represents the final milestone prior to vaccine distribution. Distribution is beginning immediately, consistent with a supply agreement with the US government in which various government agencies will manage the allocation and distribution. There is no impact on Pfizer's A2/Prime-1 ratings or the stable outlook. The approval ... (full story)